Taming TNF: strategies to restrain this proinflammatory cytokine.

[1]  G. Firestein,et al.  Anticytokine therapy in rheumatoid arthritis. , 1997, The New England journal of medicine.

[2]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[3]  M. Kamm,et al.  Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease , 1997, The Lancet.

[4]  T. Greten,et al.  Endogenous Adenosine Curtails Lipopolysaccharide‐Stimulated Tumour Necrosis Factor Synthesis , 1997, Scandinavian journal of immunology.

[5]  D. Lalloo,et al.  Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. , 1996, The New England journal of medicine.

[6]  B. Beutler,et al.  Tumor necrosis factor and the Jarisch-Herxheimer reaction. , 1996, The New England journal of medicine.

[7]  G. Hartmann,et al.  Oligodeoxynucleotides Enhance Lipopolysaccharide-Stimulated Synthesis of Tumor Necrosis Factor: Dependence on Phosphorothioate Modification and Reversal by Heparin , 1996, Molecular medicine.

[8]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[9]  B. Beutler,et al.  The tumor necrosis factor ligand and receptor families. , 1996, The New England journal of medicine.

[10]  T. Greten,et al.  Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis. , 1996, European journal of pharmacology.

[11]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[12]  K. Tracey,et al.  Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone , 1996, The Journal of experimental medicine.

[13]  A. Cosimi,et al.  Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. , 1996, Transplantation.

[14]  D. Hommes,et al.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.

[15]  P. Ghezzi,et al.  Ciliary Neurotrophic Factor Inhibits Brain and Peripheral Tumor Necrosis Factor Production and, When Coadministered with Its Soluble Receptor, Protects Mice From Lipopolysaccharide Toxicity , 1995, Molecular Medicine.

[16]  S. Endres,et al.  Exogenous and endogenous nitric oxide attenuates tumor necrosis factor synthesis in the murine macrophage cell line RAW 264.7. , 1995, Journal of immunology.

[17]  I. Schmidt-Wolf,et al.  Cytokines and gene therapy. , 1995, Immunology today.

[18]  G. Koch,et al.  Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .

[19]  A. Fontana,et al.  The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis , 1995, Nature Medicine.

[20]  S. Endres,et al.  Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids , 1995, European journal of immunology.

[21]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[22]  J. Dayer,et al.  Interleukin-1, tumor necrosis factor and their specific inhibitors. , 1994, European cytokine network.

[23]  W. Buurman,et al.  Differential regulatory effects of adenosine on cytokine release by activated human monocytes. , 1994, Journal of immunology.

[24]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[25]  J. Woody,et al.  Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.

[26]  M. Krönke,et al.  Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling , 1994, Cell.

[27]  M. Goldman,et al.  The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice , 1994, The Journal of experimental medicine.

[28]  R. Bast,et al.  Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor , 1994, Nature.

[29]  M. Gerhart,et al.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing , 1994, Nature.

[30]  E. Lalli,et al.  Signal transduction and gene regulation: the nuclear response to cAMP. , 1994, The Journal of biological chemistry.

[31]  C. Andresen,et al.  Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. , 1994, American journal of respiratory and critical care medicine.

[32]  P. Vandenabeele,et al.  Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemia , 1994, European journal of immunology.

[33]  B. Aggarwal,et al.  Inhibition by all‐trans‐retinoic acid of tumor necrosis factor and nitric oxide production by peritoneal macrophages , 1994, Journal of leukocyte biology.

[34]  B. Beutler,et al.  Receptor-mediated label-transfer assay (RELAY): a novel method for the detection of plasma tumor necrosis factor at attomolar concentrations. , 1994, Journal of immunological methods.

[35]  C. Weber,et al.  Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. , 1993, Journal of immunology.

[36]  A. Eggermont,et al.  Effects of recombinant tumour necrosis factor (rTNF‐α) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF‐α administration in isolated limb perfusions in cancer patients , 1993, European journal of clinical investigation.

[37]  S. Endres,et al.  Prostacyclin analogs suppress the synthesis of tumor necrosis factor-alpha in LPS-stimulated human peripheral blood mononuclear cells. , 1993, Immunopharmacology.

[38]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[39]  D. Morrison,et al.  Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. , 1993, Journal of immunology.

[40]  G. Kaplan,et al.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.

[41]  T. Mak,et al.  Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection , 1993, Cell.

[42]  C. Dinarello,et al.  Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. , 1993, JAMA.

[43]  S. Endres,et al.  The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. , 1993, International journal of immunopharmacology.

[44]  S. Tomlanovich,et al.  Pentoxifylline reduces the first-dose reactions following OKT3. , 1993, Transplantation proceedings.

[45]  J. Vincent,et al.  Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis , 1993, Critical care medicine.

[46]  D. Remick,et al.  Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer Reaction of relapsing fever , 1992, The Journal of experimental medicine.

[47]  E. Thompson,et al.  In vivo relationship of tumor necrosis factor-α to blood-brain barrier damage in patients with active multiple sclerosis , 1992, Journal of Neuroimmunology.

[48]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[49]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[50]  I. Bedrosian,et al.  Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. , 1991, Cytokine.

[51]  C. Unger,et al.  Tumor necrosis factor induces rapid production of 1'2'diacylglycerol by a phosphatidylcholine-specific phospholipase C , 1991, The Journal of experimental medicine.

[52]  M. Savage,et al.  Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. , 1991, Gut.

[53]  B. Undem,et al.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. , 1991, Thorax.

[54]  C. Dinarello,et al.  Histamine suppresses gene expression and synthesis of tumor necrosis factor alpha via histamine H2 receptors , 1991, The Journal of experimental medicine.

[55]  A. Mantovani,et al.  Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock , 1991, Journal of Experimental Medicine.

[56]  M. Ohmichi,et al.  Detection of endogenous cytokines in sera or in lymph nodes obtained from patients with sarcoidosis , 1991, Clinical and experimental immunology.

[57]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[58]  Jiahuai Han,et al.  Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway , 1990, The Journal of experimental medicine.

[59]  J. Lumley,et al.  Monoclonal antibody to TN F in severe septic shock , 1990, The Lancet.

[60]  W. Lehmacher,et al.  Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. , 1990, Blood.

[61]  M. Gougerot-Pocidalo,et al.  Raised plasma levels of tumor necrosis factor in heart allograft rejection. , 1990, Transplantation proceedings.

[62]  P. Vassalli,et al.  Tumor‐Necrosis Factor and other Cytokines in Cerebral Malaria: Experimental and Clinical Data , 1989, Immunological reviews.

[63]  P. Brandtzaeg,et al.  Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response , 1989, The Journal of experimental medicine.

[64]  L. Grimaldi,et al.  Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis , 1989, Annals of neurology.

[65]  D. Wallach,et al.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. , 1989, The Journal of biological chemistry.

[66]  R. Strieter,et al.  Cyclosporine A inhibits TNF production without decreasing TNF mRNA levels. , 1989, Biochemical and biophysical research communications.

[67]  M. Molyneux,et al.  Tumor necrosis factor and disease severity in children with falciparum malaria. , 1989, The New England journal of medicine.

[68]  C. Ferran,et al.  Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. , 1989, The New England journal of medicine.

[69]  C. Maury,et al.  Circulating tumour necrosis factor‐α (cachectin) in myocardial infarction , 1989 .

[70]  P. Pelkonen,et al.  Elevated circulating tumor necrosis factor-alpha in patients with Kawasaki disease. , 1989, The Journal of laboratory and clinical medicine.

[71]  D. I. Stuart,et al.  Structure of tumour necrosis factor , 1989, Nature.

[72]  P. Weber,et al.  The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. , 1989, The New England journal of medicine.

[73]  P. Brandtzaeg,et al.  The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome , 1989, The Journal of experimental medicine.

[74]  D. Baltimore,et al.  I kappa B: a specific inhibitor of the NF-kappa B transcription factor. , 1988, Science.

[75]  C. Maury,et al.  Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. , 1988, The American journal of medicine.

[76]  D. Remick,et al.  Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. , 1988, The Journal of biological chemistry.

[77]  C. Maury,et al.  Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection , 1987, The Journal of experimental medicine.

[78]  H. Shepard,et al.  Inhibition of cytokine production by cyclosporin A and transforming growth factor beta , 1987, The Journal of experimental medicine.

[79]  B. Beutler,et al.  Cachectin and tumour necrosis factor as two sides of the same biological coin , 1986, Nature.

[80]  J. Strickler,et al.  Molecular cloning of the complementary DNA for human tumor necrosis factor. , 1985, Science.

[81]  D. Goeddel,et al.  Human tumor necrosis factor. Production, purification, and characterization. , 1985, The Journal of biological chemistry.

[82]  Bharat B. Aggarwal,et al.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin , 1984, Nature.

[83]  H. Wachtel,et al.  Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors , 1983, Neuropharmacology.

[84]  W. Coley,et al.  THE TREATMENT OF MALIGNAT TUMORS BY REPEATED INOCULATIONS OF ERYSIPELAS: WITH A REPORT OF TEN ORIGINAL CASES , 1893 .

[85]  Charles,et al.  The interleuldn-1 family: 10 years of discovery’ , 2020 .

[86]  G. Hartmann,et al.  Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents. , 1997, European journal of pharmacology.

[87]  G. Hartmann,et al.  Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides. , 1996, Antisense and Nucleic Acid Drug Development.

[88]  G. Fantuzzi,et al.  Chlorpromazine inhibits tumour necrosis factor synthesis and cytotoxicity in vitro. , 1995, Immunology.

[89]  B. Klein,et al.  Cytokine-binding proteins: stimulating antagonists. , 1995, Immunology today.

[90]  P. Baeuerle,et al.  Function and activation of NF-kappa B in the immune system. , 1994, Annual review of immunology.

[91]  K. Tracey,et al.  Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. , 1994, Annual review of medicine.

[92]  D. Rush,et al.  Production of tumor necrosis factor alpha and hemodialysis. , 1993, Nephron.

[93]  P. Vassalli,et al.  The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.

[94]  R. Gerzer,et al.  Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells. , 1991, Immunology.

[95]  C. Maury,et al.  Cachectin/tumour necrosis factor-alpha in the circulation of patients with rheumatic disease. , 1989, International journal of tissue reactions.

[96]  T. Shirai,et al.  Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor , 1985, Nature.